gp63 in Stable Cationic Liposomes Confers Sustained Vaccine Immunity to Susceptible BALB/c Mice Infected with<i>Leishmania donovani</i>

Bhowmick, Swati; Ravindran, Rajesh; Ali, Nahid

doi:10.1128/iai.00611-07

Cited by 106 publications

(82 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other authors have already observed that immunization with gp63 encapsulated in neutral (Jaafari et al 2006) and cationic liposomes (Bhowmick et al 2008) and native PSA-2 antigen along with Cryptosporidium parvum (Handman et al 1995;Sjolander et al 1998) protected mice through Th1 cell-mediated immune response; however, recombinant PSA-2 failed to confer protection despite the induction of Th1 response (Sjolander et al 1998).…”

Section: New Perspectives For Applications Of Proteoliposomesmentioning

confidence: 99%

“…Several Leishmania proteins have been identified, and the most comprehensively studied antigens include glycoprotein 63 (gp63) (Xu et al 1995;Bhowmick et al 2008), glycoprotein 46 (gp46) or parasite surface antigen 2 (PSA-2) (McMahon-Pratt et al 1992, 1993, Leishmania homologue of receptors for activated C kinase (LACK) (Coelho et al 2003;Pinto et al 2004), and focused mannose ligand (FML) (Palatnik de Sousa et al 1994;). …”

Section: New Perspectives For Applications Of Proteoliposomesmentioning

confidence: 99%

See 1 more Smart Citation

Proteoliposomes in nanobiotechnology

et al. 2012

View full text Add to dashboard Cite

Proteoliposomes are systems that mimic lipid membranes (liposomes) to which a protein has been incorporated or inserted. During the last decade, these systems have gained prominence as tools for biophysical studies on lipid-protein interactions as well as for their biotechnological applications. Proteoliposomes have a major advantage when compared with natural membrane systems, since they can be obtained with a smaller number of lipidic (and protein) components, facilitating the design and interpretation of certain experiments. However, they have the disadvantage of requiring methodological standardization for incorporation of each specific protein, and the need to verify that the reconstitution procedure has yielded the correct orientation of the protein in the proteoliposome system with recovery of its functional activity. In this review, we chose two proteins under study in our laboratory to exemplify the steps necessary for the standardization of the reconstitution of membrane proteins in liposome systems: (1) alkaline phosphatase, a protein with a glycosylphosphatidylinositol anchor, and (2) Na,K-ATPase, an integral membrane protein. In these examples, we focus on the production of the specific proteoliposomes, as well as on their biochemical and biophysical characterization, with emphasis on studies of lipid-protein interactions. We conclude the chapter by highlighting current prospects of this technology for biotechnological applications, including the construction of nanosensors and of a multiprotein nanovesicular biomimetic to study the processes of initiation of skeletal mineralization.

show abstract

Section: New Perspectives For Applications Of Proteoliposomesmentioning

confidence: 99%

Section: New Perspectives For Applications Of Proteoliposomesmentioning

confidence: 99%

Proteoliposomes in nanobiotechnology

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Whether complete parasite elimination can be achieved by using a liposomal drug formulation remains an open question. In addition to the drug targeting to infection sites, liposomes may exert an additional synergistic effect related to their immunoadjuvant properties, for instance, by facilitating Leishmania antigen presentation to immunocompetent cells (8,10). To improve the efficacy of treatment with our liposome formulation, increasing each dose of Sb is probably not appropriate, since this will result in a lipid dose higher than 25 mg of lipid/kg of body weight (used in our study), which may increase the saturation of the liver and impair its physiological function.…”

Section: Vol 52 2008 Reduced Tissue Parasitic Load and Infectivity mentioning

confidence: 99%

Reduced Tissue Parasitic Load and Infectivity to Sand Flies in Dogs Naturally Infected by Leishmania ( Leishmania ) chagasi following Treatment with a Liposome Formulation of Meglumine Antimoniate

Ribeiro¹,

Moura²,

Pimentel³

et al. 2008

Antimicrob Agents Chemother

View full text Add to dashboard Cite

The toxicity and antileishmanial effectiveness of a novel liposome formulation of meglumine antimoniate in mongrel dogs with visceral leishmaniasis (VL) obtained from a region where VL is endemic in Brazil have been investigated. Groups of 12 animals received by the intravenous route four doses (with 4-day intervals) of either liposomal meglumine antimoniate (group I [GI], 6.5 mg Sb/kg of body weight/dose), empty liposomes (GII), or isotonic saline (GIII). Evaluation of markers of hematopoietic, hepatic, and renal functions before and just after treatment showed no significant change. On the other hand, transitory adverse reactions, including prostration, defecation, tachypnea, and sialorrhea, were observed during the first 15 min after injections in GI and GII. Parasitological evaluation of sternal bone marrow 4 days after the last dose showed a significant reduction of parasite burden in GI, compared to the other groups. Immunocytochemical evaluations of the skin, bone marrow, cervical lymph nodes, livers, and spleens of dogs for parasites, 150 days after treatment, indicated significant parasite suppression (higher than 95.7%) in the lymph nodes, livers, and spleens of GI, compared to control groups. Feeding of Lutzomyia longipalpis phlebotomines on dogs from GI, 150 days after treatment, resulted in a significant reduction of sand fly infection efficiency, compared to feeding on animals from GII and GIII. This is the first report of both long-term parasite suppression and reduction of infectivity to sand flies in naturally infected dogs following treatment with a liposome-encapsulated drug. Importantly, this was achieved using a 20-fold-lower cumulative dose of Sb than is used for conventional antimonial treatment.

show abstract

“…While liposomes have reached the market as carriers of drugs [6], and with several papers showing positive results using liposomal vaccine adjuvants for diseases such as HIV [7][8][9], tuberculosis [10,11], malaria [12][13][14] and leshmaniasis [1,15], liposomal systems have a real chance of becoming the vaccine adjuvants of the future.…”

mentioning

confidence: 99%